409 results match your criteria Biologics[Journal]


Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases.

Biologics 2020 15;14:47-51. Epub 2020 Jun 15.

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Introduction: The better understanding of the molecular mechanisms, which drive the pathological process in the gut of patients with Crohn's disease (CD) and patients with ulcerative colitis (UC), the major forms of inflammatory bowel diseases (IBD) in humans, has facilitated the development of novel therapeutic compounds. Among these, antisense oligonucleotides (ASOs) have been used to inhibit the expression of molecules, which sustain the IBD-associated mucosal inflammation.

Areas Covered: In this short review, we summarize experimental and clinical data on the use of ASOs in IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S257638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305016PMC

Galanin Receptors as Drug Target for Novel Antidepressants: Review.

Biologics 2020 21;14:37-45. Epub 2020 Apr 21.

College of Medicine and Health Sciences, Department of Anesthesia, Adigrat University, Adigrat, Ethiopia.

Galanin (GAL) is a 29-amino-acid neuropeptide that serves multiple physiological functions throughout the central and peripheral nervous system. Its role involves in a range of physiological and pathological functions including control of food intake, neuro-protection, neuronal regeneration, energy expenditure, reproduction, water balance, mood, nociception and various neuroendocrine functions. The use of currently available antidepressant drugs raises concerns regarding efficacy and onset of action; therefore, the need for antidepressants with novel mechanisms is increasing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S240715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183331PMC

Autophagy Regulates the Stemness of Cervical Cancer Stem Cells [Retraction].

Authors:

Biologics 2020 26;14:35. Epub 2020 Mar 26.

[This retracts the article DOI: 10.2147/BTT.S134920. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S254584DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117093PMC

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy.

Biologics 2020 14;14:23-34. Epub 2020 Feb 14.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S202746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027838PMC
February 2020

Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study.

Biologics 2020 11;14:13-21. Epub 2020 Feb 11.

Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.

Objective: This open-label study evaluated the effects of combined tocilizumab (TCZ) and disease-modifying antirheumatic drugs (DMARDs) on magnetic resonance imaging (MRI) changes in synovial membrane enhancement, bone marrow edema (BME), and erosions in the wrist and hand joints of rheumatoid arthritis (RA) patients inadequately responding to DMARDs alone.

Methods: The efficacy of intravenous TCZ 8 mg/kg administered every four weeks for 48 weeks was evaluated on six occasions. The primary endpoints were the changes in the extent and degree of wrist synovitis as measured using the RA MRI Score (RAMRIS) and dynamic, gadolinium-enhanced 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S209873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023854PMC
February 2020

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.

Biologics 2020 10;14:1-11. Epub 2020 Jan 10.

Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S236433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966952PMC
January 2020

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up.

Biologics 2019 25;13:191-200. Epub 2019 Nov 25.

Department of Gastroenterology, Base Hospital, New Delhi, India.

Background: Adalimumab (ADA) is approved for the management of lcerative colitis (UC) not responding to conventional therapy. Use of biologics in resource-constrained settings is very challenging. Currently, real-life data on the safety and efficacy of ADA biosimilar (Exemptia) in steroid-refractory UC patients are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S214518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883941PMC
November 2019

Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats.

Biologics 2019 30;13:179-190. Epub 2019 Aug 30.

Department of Internal Medicine, Division of Endocrinology and Metabolic, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.

Background: Podocyte injury and its subsequent detachment play a critical role in the development and progression of diabetic nephropathy (DN). The objective of this study was to investigate the effect of rosmarinic acid (RA) in preventing podocyte detachment and inhibiting the progression of DN in streptozotocin (STZ)-induced diabetic in rats.

Methods: We used 20 adult male Wistar rats as experimental animals, which were randomly divided into 5 groups (n=4 per group): nondiabetic rat group (negative control) and 4 groups of STZ-induced diabetic rats, namely, 1 group untreated diabetic rats (positive control) and 3 groups treated diabetic rats with RA 75 mg/kg, telmisartan (TMS) 1 mg/kg and combination of RA 75 mg/kg with TMS 1 mg/kg), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S214820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722456PMC
August 2019
1 Read

Remicade (infliximab): 20 years of contributions to science and medicine.

Biologics 2019 30;13:139-178. Epub 2019 Jul 30.

Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USA.

On August 24, 1998, Remicade (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn's disease. Subsequently, Remicade was approved in another five adult and two pediatric indications both in the USA and across the globe. In the 20 years since this first approval, Remicade has made several important contributions to the advancement of science and medicine: 1) clinical trials with Remicade established the proof of concept that targeted therapy can be effective in immune-mediated inflammatory diseases; 2) as the first monoclonal antibody approved for use in a chronic condition, Remicade helped in identifying methods of administering large, foreign proteins repeatedly while limiting the body's immune response to them; 3) the need to establish Remicade's safety profile required developing new methods and setting new standards for postmarketing safety studies, specifically in the real-world setting, in terms of approach, size, and duration of follow-up; 4) the study of Remicade has improved our understanding of TNF's role in the immune system, as well as our understanding of the pathophysiology of a range of diseases characterized by chronic inflammation; and 5) Remicade and other TNF inhibitors have transformed treatment practices in these chronic inflammatory diseases: remission has become a realistic goal of therapy and long-term disability resulting from structural damage can be prevented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S207246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679695PMC

Antitumor and antibacterial properties of virally encoded cationic sequences.

Biologics 2019 25;13:117-126. Epub 2019 Jun 25.

Laboratoire E3 des Phosphatases-Unité RMN, Institut Pasteur, Paris, France.

The objective of this study was to test our Viral Quinta Columna Strategy (VQCS), a new biological hypothesis predicting that specific multifunctional virally encoded cationic domains may have the capacity to penetrate human cells and interact with PP2A proteins to deregulate important human intracellular pathways, and may display LL37 cathelicidin-like antagonistic effects against multiple pathogens such as bacteria or viruses. We comparatively analyzed the host defense properties of adenodiaphorins and of some specific cationic sequences encoded by different viruses using two distinct biological models: U87G, a well-characterized cell tumor model; and a group B NEM316 ΔdltA, highly sensitive to LL37 cathelicidin. We found that the adenovirus type 2 E4orf4 is a cell-permeable protein containing a new E4orf4 protein transduction domain, named large adenodiaphorin or LadD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S201287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599856PMC

Clinical utility of ramucirumab in non-small-cell lung cancer.

Authors:
Dipesh Uprety

Biologics 2019 22;13:133-137. Epub 2019 Jul 22.

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and approximately 70% of patients with NSCLC have locally advanced or metastatic disease at presentation. In NSCLC patients with advanced or metastatic disease, second line treatment with chemotherapy is associated with a poor response rate. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-utility-of-ramucirumab-in
Publisher Site
http://dx.doi.org/10.2147/BTT.S175034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659776PMC
July 2019
2 Reads

Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab.

Biologics 2019 14;13:111-116. Epub 2019 Jun 14.

Division of Rheumatology, Department of Paediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Systemic polyarteritis nodosa (PAN) is a rare form of necrotizing vasculitis in children. Recurrent episodes of abdominal aneurysm ruptures are uncommon and life-threatening condition in children. Failures of response to immunosuppressive medications and radiological intervention also lead to high mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S204726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585408PMC
June 2019
4 Reads

TRIP6 functions as a potential oncogene and facilitated proliferation and metastasis of gastric cancer.

Biologics 2019 11;13:101-110. Epub 2019 Jun 11.

Department of General Surgery, Suqian First People's Hospital, Suqian, Jiangsu, People's Republic of China.

Increasing evidence suggests that TRIP6 has been considered to be aberrantly regulated in several malignancies and involved in tumor growth and metastasis. However, the biological role and prognostic significance of TRIP6 in gastric cancer (GC) still remains unclear. TRIP6 expression was determined in matched GC tissues and adjacent normal tissues by western blot and real-time PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S191863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6576131PMC
June 2019
5 Reads

Therapeutic drug monitoring of biologics in psoriasis.

Biologics 2019 5;13:127-132. Epub 2019 Jul 5.

National Skin Centre, Singapore;

Biologics are an important component of the armamentarium of drugs in the treatment of moderate to severe psoriasis. There is increasing evidence that therapeutic drug monitoring (TDM) encompassing the measurement of trough concentrations and anti-drug antibodies (ADA), together with clinical response is emerging as a valuable tool for clinical decision making. It aids in targeted dose adjustments in patients with low drug concentrations, monitoring of adherence and assessment of patients who lose response to biologics or do not respond at all. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S188286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613538PMC
July 2019
12 Reads

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG).

Biologics 2019 27;13:97-99. Epub 2019 May 27.

Department of Pediatric, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.

We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S203753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554516PMC
May 2019
6 Reads

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic.

Biologics 2019 22;13:89-95. Epub 2019 May 22.

Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.

In the last decades, the increasing evidence concerning inflammation mechanisms underlying severe eosinophilic asthma has highlighted new potential therapeutic targets and has paved the way to new selective biologic drugs. Understanding the mechanism of action and the clinical outcomes of a particular drug along with the clinical and biological characteristics of the patient population for which that drug was intended may ensure appropriate selection of patients that will respond to that drug. Under this perspective, the present review will focus on the mechanisms of action and clinical evidence of benralizumab as a treatment option for severe eosinophilic asthma, in order to provide a concise overview and a reference for clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S157183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535408PMC
May 2019
29 Reads

Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.

Biologics 2019 20;13:83-87. Epub 2019 May 20.

Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russian Federation.

Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S199100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535620PMC
May 2019
6 Reads

Dupilumab side effect in a patient with atopic dermatitis: a case report study.

Biologics 2019 13;13:79-82. Epub 2019 May 13.

Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S195512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526326PMC
May 2019
14 Reads

Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Biologics 2019 13;13:53-78. Epub 2019 May 13.

Department of Dermatology, National Skin Centre, Singapore, Singapore.

Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways in immune dysregulation in moderate/severe hidradenitis suppurativa (HS) has helped in developing new regimens. We aim to review the use of different immunomodulatory therapies used to manage HS. A comprehensive literature search was conducted on the PubMed and Clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S199862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526329PMC
May 2019
3 Reads

Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy.

Biologics 2019 1;13:33-51. Epub 2019 May 1.

School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.

Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved treatment outcomes by offering enhanced specificity to reduce severe side effects experienced with conventional chemotherapy. Notwithstanding, poor tumor tissue penetration and the heterogeneous distribution achieved therein are prominent drawbacks that hamper the clinical efficacy of therapeutic antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S166310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503308PMC
May 2019
3 Reads

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

Biologics 2019 9;13:23-31. Epub 2019 Apr 9.

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Ulcerative colitis (UC) still has no definitive cure since its etiology remains unclear. In recent years, considerable progress has been made with regard to our knowledge of the pathogenesis of UC. Advances in biotechnology have led to the development of biologic therapies which selectively target single key mediators or receptors involved in the pathogenesis of the disease - ie, tumor necrosis factor (TNF)-α, integrin, interleukins 12/23. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S179006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497489PMC
April 2019
1 Read

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience.

Biologics 2019 3;13:13-21. Epub 2019 Jan 3.

Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy.

Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn's disease (CD) and the published experience as rescue therapy is limited.

Objectives: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed previous infliximab treatment, with a minimum follow-up of 6 months.

Methods: In this multicenter study, data on demographics, clinical activity, growth, laboratory values (CRP) and adverse events were collected from CD patients during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S183088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322517PMC
January 2019
38 Reads

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.

Biologics 2019 21;13:1-12. Epub 2018 Dec 21.

Cancer Center,

Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system which accounts for 8% of childhood cancers. Most NBs express high levels of the disialoganglioside GD2. Several antibodies have been developed to target GD2 on NB, including the human/mouse chimeric antibody ch14. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S114530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306059PMC
December 2018
6 Reads

The role of microfluidics in protein formulations with pre-programmed functional characteristics.

Biologics 2018 3;12:191-197. Epub 2018 Dec 3.

Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong, China,

Protein-based therapies hold great promise for treating many diseases. Nevertheless, the challenges of producing therapies with targeted attributes via standardized processes may hinder the development of protein formulations and clinical translation of the advanced therapies. Microfluidics represents a promising technology to develop protein formulations with pre-programmed functional characteristics, including size, morphology, and controlled drug release property. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-role-of-microfluidics-in-prote
Publisher Site
http://dx.doi.org/10.2147/BTT.S126725DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284529PMC
December 2018
3 Reads

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results.

Biologics 2018 27;12:171-182. Epub 2018 Nov 27.

Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan,

Purpose: We evaluated the clinical responses and radiographic outcomes of 90 patients with rheumatoid arthritis (RA) undergoing continuous or dose-adjusted infliximab treatment over 104 weeks.

Patients And Methods: Patients received 3 mg/kg infliximab continuously (the contin group; n=50), or the dose escalation and de-escalation of infliximab (3, 6, and 10 mg/kg) from week 14 (the adjusted group; n=40) based on the patient's Disease Activity Score in 28 joints (DAS28). The retention rate, clinical response, and radiographic assessment were determined at week 104. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S187998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267494PMC
November 2018
1 Read

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation.

Biologics 2018 30;12:183-190. Epub 2018 Nov 30.

Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, Shaanxi, China,

Purpose: Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, and the combination of EGFR-TKIs and chemotherapy has been used for advanced NSCLC patients; however, little is known about the efficacy of the direct comparison among them.

Patients And Methods: The demographic and clinical characteristics of 92 patients harboring advanced NSCLC with EGFR mutation were retrospectively reviewed. We evaluated the effects of EGFR-TKIs, chemotherapy, and EGFR-TKIs plus chemotherapy on advanced NSCLC patients with EGFR mutations, and the efficacy of combination of chemotherapy and EGFR-TKIs vs chemotherapy or EGFR-TKIs alone in advanced NSCLC patients was evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S169305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280904PMC
November 2018
18 Reads

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product.

Biologics 2018 23;12:159-170. Epub 2018 Nov 23.

Sun Pharmaceutical Industries Limited, Tandalja, Vadodara 390 012, India,

Background: Cell surface protein, CD20, is extensively expressed on the surface of B cells. Antibodies targeting CD20 protein are being used to treat B-cell malignancies and B-cell mediated autoimmune diseases. Considering the cost of therapy with innovator monoclonal antibodies for these diseases, development of biosimilar products for the treatment of such diseases provides affordable solution to rising healthcare costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S187744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257079PMC
November 2018
15 Reads

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

Biologics 2018 12;12:151-158. Epub 2018 Nov 12.

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.

Design: Retrospective observational study.

Setting: Real-life clinical setting in 5 Italian local health units. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S168691DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237141PMC
November 2018
3 Reads

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.

Biologics 2018 8;12:143-149. Epub 2018 Nov 8.

Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands,

Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-effects-of-golimumab-treatment
Publisher Site
http://dx.doi.org/10.2147/BTT.S176806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231442PMC
November 2018
12 Reads

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.

Biologics 2018 25;12:127-134. Epub 2018 Oct 25.

Department of Rheumatology, Guven Hospital, Ankara, Turkey.

Purpose: This study compared treatment patterns of Turkish patients with a diagnosis of rheumatoid arthritis (RA) who were treated with innovator Remicade (infliximab [IFX]) and either continued IFX or switched to CT-P13.

Materials And Methods: Adult RA patients with ≥1 IFX claim were identified from the Turkish Ministry of Health database. Eligible patients initiated and continued IFX treatment (continuers cohort [CC]) or initiated IFX and switched to CT-P13 (switchers cohort [SC]) during the study period. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/analysis-of-real-world-treatment-p
Publisher Site
http://dx.doi.org/10.2147/BTT.S172337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207267PMC
October 2018
29 Reads

Two decades with omalizumab: what we still have to learn.

Biologics 2018 26;12:135-142. Epub 2018 Oct 26.

Department of Medicine and Surgery, University of Parma, Parma, Italy.

From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on therapy against severe uncontrolled asthma. Thanks to controlled trials supporting its efficacy, omalizumab has also been licensed for the treatment of chronic spontaneous urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S180846DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208531PMC
October 2018
27 Reads

Designing of CD8 and CD8-overlapped CD4 epitope vaccine by targeting late and early proteins of human papillomavirus.

Biologics 2018 2;12:107-125. Epub 2018 Oct 2.

Centre of Interdisciplinary Science - Computational Life Sciences, College of Food Science and Engineering, Henan University of Technology, Zhengzhou, China,

Background And Aim: Human papillomavirus (HPV) is an oncogenic agent that causes over 90% of cases of cervical cancer in the world. Currently available prophylactic vaccines are type specific and have less therapeutic efficiency. Therefore, we aimed to predict the potential species-specific and therapeutic epitopes from the protein sequences of HPV45 by using different immunoinformatics tools. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/designing-of-cd8-and-cd8-overlappe
Publisher Site
http://dx.doi.org/10.2147/BTT.S177901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174296PMC
October 2018
75 Reads

A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population.

Biologics 2018 2;12:97-106. Epub 2018 Oct 2.

Guven Hospital, Department of Rheumatology, Ankara, Turkey.

Purpose: Biosimilar IFX (CT-P13) received marketing approval in Turkey for treatment of rheumatologic diseases, including ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Population data on real-world treatment patterns of CT-P13 following marketing approval in European countries are largely unreported. This study examined the prescribing and medication utilization patterns of innovator infliximab (IFX) and CT-P13 in Turkey for patients with RA or IBD naïve to either IFX. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/a-descriptive-analysis-of-real-wor
Publisher Site
http://dx.doi.org/10.2147/BTT.S172241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174299PMC
October 2018
14 Reads

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Biologics 2018 30;12:87-95. Epub 2018 Aug 30.

Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy.

Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent savings.

Aims: To review the pharmacodynamics, pharmacokinetics, efficacy, and safety of ETN biosimilars when employed as first-line therapy or after transition from re-ETN. Patients' acceptability was also addressed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S126854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121755PMC
August 2018
3 Reads

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.

Biologics 2018 20;12:75-86. Epub 2018 Aug 20.

Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing 400042, China,

Aim: Although EGFR tyrosine kinase inhibitors (TKIs) have shown dramatic effects against sensitizing EGFR mutations in non-small cell lung cancer (NSCLC), ~20%-30% of NSCLC patients with EGFR-sensitive mutation exhibit intrinsic resistance to EGFR-TKIs. The purpose of the current study was to investigate the enhanced antitumor effect of metformin (Met), a biguanide drug, in combination with gefitinib (Gef) in primary resistant human lung cancer cells and the associated molecular mechanism.

Experimental Design: H1975 cell line was treated with Met and/or Gef to examine the inhibition of cell growth and potential mechanism of action by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Ki67 incorporation assay, flow cytometry analysis, small interfering RNA technology, Western blot analysis and xenograft implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S166867DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108345PMC
August 2018
4 Reads

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease.

Biologics 2018 19;12:69-73. Epub 2018 Jul 19.

Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan,

Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn's disease. However, some problems have been identified during clinical use of this class of drugs, such as secondary treatment failure, in which the drugs become progressively less effective with time, and the development of paradoxical reactions such as psoriatic skin symptoms. Thus, while anti-TNFα drugs are used to treat psoriasis, they can sometimes also cause paradoxical psoriasis, characterized by the appearance of psoriasis-like eruptions, which has recently begun to attract attention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S169326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055910PMC
July 2018
3 Reads

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.

Biologics 2018 27;12:61-67. Epub 2018 Feb 27.

Department of Medicine.

Background: Tumor necrosis factor alpha (TNFα) is a key cytokine in both the pathogenesis of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and the host defense against tuberculosis (TB). Consequently, anti-TNFα medications result in an increased risk of latent TB infection (LTBI) reactivation. Here, we sought to evaluate the factors affecting the results of QuantiFERON-TB Gold In-Tube (QFT-GIT) assay as a screening tool for LTBI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S150958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834167PMC
February 2018
6 Reads

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Biologics 2018 9;12:43-60. Epub 2018 Feb 9.

PanTherapeutics, Lutry, Switzerland.

Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses - adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses - have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/new-frontiers-in-oncolytic-viruses
Publisher Site
http://dx.doi.org/10.2147/BTT.S140114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810530PMC
February 2018
7 Reads

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.

Biologics 2018 31;12:37-41. Epub 2018 Jan 31.

Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. Giovanni di Dio, Florence, Italy.

Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases.

Patients And Methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA). Serum drug and ADA levels were determined using Lisa-Tracker Duo, the ADA-positive samples underwent an inhibition test, and the true-positive samples underwent genetic HLA typing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S145941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797458PMC
January 2018
4 Reads

Analytical characterization of recombinant hCG and comparative studies with reference product.

Biologics 2018 30;12:23-35. Epub 2018 Jan 30.

Sun Pharmaceutical Industries Limited.

Introduction: Regulatory agencies recommend a stepwise approach for demonstrating biosimilarity between a proposed biosimilar and reference biological product emphasizing for functional and structural characterization to trace if there is any difference which may impact safety and efficacy. We studied the comparative structural and biological attributes of recombinant human chorionic gonadotropin (rhCG), SB005, with reference product, Ovidrel and Ovitrelle. Recombiant hCG was approved in 2000 by the US Food and Drug Administration for the induction of final follicular maturation, early luteinization in infertile women as part of assisted reproductive technology program. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/analytical-characterization-of-rec
Publisher Site
http://dx.doi.org/10.2147/BTT.S141203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796461PMC
January 2018
54 Reads

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent infection.

Biologics 2018 18;12:11-21. Epub 2018 Jan 18.

Internal Medicine and Infectious Diseases, Infection Prevention and Epidemiology, Detroit Medical Center, Wayne State University, Detroit, MI, USA.

infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%-35% risk after primary CDI to 35%-65% risk after the first recurrent episode. Recurrent CDI is one of the most challenging and a very difficult to treat infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S127099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779312PMC
January 2018
4 Reads

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.

Biologics 2018 12;12:1-9. Epub 2018 Jan 12.

Pfizer, Brussels, Belgium.

Tumor necrosis factor-α (TNF-α) inhibitors are increasingly becoming the standard of care for treating a number of inflammatory diseases. However, treatment with TNF-α inhibitors carries an inherent risk of compromising the immune system, resulting in an increased susceptibility to infections and malignancies. This increased risk of infection is of particular concern in Asia, Eastern Europe, and Latin America where tuberculosis (TB) and viral hepatitis are endemic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S148606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769557PMC
January 2018
25 Reads

Anti-angiogenic effects of biotechnological therapies in rheumatic diseases.

Biologics 2017 14;11:123-128. Epub 2017 Dec 14.

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School.

Introduction: Angiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases.

Methods: This review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/anti-angiogenic-effects-of-biotech
Publisher Site
http://dx.doi.org/10.2147/BTT.S143674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733924PMC
December 2017
9 Reads

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.

Biologics 2017 6;11:115-122. Epub 2017 Dec 6.

Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA.

Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S108818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723116PMC
December 2017
14 Reads

Anticholinesterase constituents from the leaves of L. (Anacardiaceae).

Biologics 2017 2;11:107-114. Epub 2017 Aug 2.

Department of Pharmacognosy, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun, Nigeria.

has been used in traditional medicine for the management of several diseases, including memory loss. This study aimed to evaluate the cholinesterase inhibitory activity of the methanol extract of the leaves and its derived fractions, as well as carry out detailed phytochemical investigations leading to the isolation and characterization of bioactive compounds from the plant. The acetyl cholinesterase (AChE) and butyryl cholinesterase (BUChE) inhibitory activities were evaluated by colorimetric and thin-layer chromatography bioautographic assay techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S136011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546590PMC
August 2017
5 Reads

Epigenetic memory of oxidative stress: does nephrilin exert its protective effects via Rac1?

Biologics 2017 17;11:97-106. Epub 2017 Jul 17.

Department of Pediatrics, Division of Pediatric Nephrology, University of Mississippi Medical Center, Jackson, MS, USA.

Aim: Nephrilin peptide, a designed inhibitor of Rictor complex (mTORC2), exerts pleiotropic protective effects in metabolic, xenobiotic and traumatic stress models. Stress can generate enduring epigenetic changes in gene function. In this work we examine the possibility that nephrilin treatment protects against acute and enduring global changes in oxidative metabolism, with a focus on the Rictor-complex-mediated activation of Rac1, a subunit of NADPH oxidase (Nox) via PKCs, Prex1 and p66shc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S136188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522666PMC
July 2017
9 Reads

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma.

Biologics 2017 27;11:81-95. Epub 2017 Jun 27.

Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK.

Mepolizumab (Nucala) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently National Institute for Health and Care Excellence (NICE; UK). It is one of several molecular therapies in development for this indication and is illustrative of the strategic trajectory for pharmaceutical drug development taken over the past decade in several disease areas. Molecular therapies offer the prospect of improved specificity and effectiveness of biological effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S93954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498675PMC
June 2017
11 Reads

Autophagy regulates the stemness of cervical cancer stem cells.

Biologics 2017 21;11:71-79. Epub 2017 Jun 21.

Hubei Key Laboratory of Embryonic Stem Cell Research.

Cancer stem cells (CSCs) are a rare population of multipotent cells with the capacity to self-renew. It has been reported that there are CSCs in cervical cancer cells. Pluripotency-associated (PA) transcription factors such as Oct4, Sox2, Nanog and CD44 have been used to isolate CSCs subpopulations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S134920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484512PMC
June 2017
39 Reads

Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn's disease.

Biologics 2017 22;11:65-69. Epub 2017 May 22.

Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan.

Currently, anti-TNFα antibodies are used to treat Crohn's disease. We report on a 45-year-old Japanese female with Crohn's disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S134508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447692PMC
May 2017
11 Reads

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties.

Biologics 2017 2;11:55-63. Epub 2017 May 2.

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.

This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S128308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422320PMC
May 2017
51 Reads